Related Experiment Video

Updated: Aug 30, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic cells

Valeria P Makarenkova1, Galina V Shurin, Irina L Tourkova

  • 1Department of Pathology, University of Pittsburgh Medical Center and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA.

Journal of Neuroimmunology
|December 4, 2003
PubMed

Insights

Tumor-derived neuroendocrine factors, including bombesin-like peptides (BLP), inhibit dendritic cell (DC) maturation and function. This suggests a new tumor escape mechanism and potential targets for cancer immunotherapy.

Area of Science:

  • Immunology
  • Neuroendocrinology
  • Oncology

Background:

  • Tumor development is influenced by neuroendocrine factors, particularly bombesin-like peptides (BLP).
  • Dendritic cells (DCs) are crucial immune regulators, and their function can be modulated by the tumor microenvironment.

Purpose of the Study:

  • To investigate the role of BLP in regulating dendritic cell (DC) maturation and function.
  • To explore the impact of specific BLP (bombesin, neuromedin B, gastrin-releasing peptide) and a BLP antagonist on DC immune responses.

Main Methods:

  • Assessed DC maturation markers (CD40, CD80, CD86) following exposure to BLP.
  • Measured interleukin-12 (IL-12) production by DCs.
  • Evaluated DC-mediated T cell activation.
  • Utilized a bombesin antagonist (D-Phe-bombesin) to assess its effect on tumor-induced immunosuppression.

Main Results:

  • Bombesin (BOM), neuromedin B (NMB), and gastrin-releasing peptide (GRP) dose-dependently inhibited DC maturation.
  • BOM and GRP suppressed IL-12 production and T cell activation by DCs.
  • The BLP antagonist partly reversed the immunosuppressive effects of tumor cells on DCs.

Conclusions:

  • BLP play a significant role in inhibiting DC maturation and function within the lung cancer microenvironment.
  • This represents a novel mechanism of tumor immune evasion.
  • BLP and their antagonists offer potential therapeutic targets for immunopharmacological cancer treatments.

More Related Videos

Human Lung Dendritic Cells: Spatial Distribution and Phenotypic Identification in Endobronchial Biopsies Using Immunohistochemistry and Flow Cytometry11:02

Human Lung Dendritic Cells: Spatial Distribution and Phenotypic Identification in Endobronchial Biopsies Using Immunohistochemistry and Flow Cytometry

Published on: January 20, 2017

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...